EUVIMEDSkopri EUVIMED
Leserbrief

Inlexzo (gemcitabine intravesical system): promising data but key questions remain

Zarmeen Azhar, Zehra Sadia

World Journal of Urology · 2025

DOI: 10.1007/s00345-025-05955-0 ↗

At a glance

Leserbrief in World Journal of Urology, 2025. Written by Zarmeen Azhar and 1 co-authors. Institution: Karachi Medical and Dental College, Karachi, Pakistan. zarmeen.azhar123@gmail.com. Major MEDLINE topics: Antimetabolites, Antineoplastic, Carcinoma in Situ, Deoxycytidine, Urinary Bladder Neoplasms. Cited 3 times so far (Crossref); 5 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Ebda abstract disponibbli.

Subjects

MeSH terms (MEDLINE)

Antimetabolites, AntineoplasticCarcinoma in SituDeoxycytidineUrinary Bladder NeoplasmsHumansAdministration, IntravesicalGemcitabine

Author keywords

BCG unresponsiveFDA approvalGemcitabine intravesical systemNon-muscle invasive bladder cancer

Substances

Antimetabolites, AntineoplasticDeoxycytidineGemcitabine

Authors and institutions

  • Karachi Medical and Dental College, Karachi, Pakistan. zarmeen.azhar123@gmail.com.
  • Karachi Medical and Dental College, Karachi, Pakistan.

Cite

APA

Azhar, Z., & Sadia, Z. (2025). Inlexzo (gemcitabine intravesical system): promising data but key questions remain. World Journal of Urology. https://doi.org/10.1007/s00345-025-05955-0

Vancouver

Azhar Z, Sadia Z. Inlexzo (gemcitabine intravesical system): promising data but key questions remain. World Journal of Urology. 2025. doi:10.1007/s00345-025-05955-0

BibTeX
@article{Azhar2025,
  author = {Azhar, Zarmeen and Sadia, Zehra},
  title = {Inlexzo (gemcitabine intravesical system): promising data but key questions remain},
  journal = {World Journal of Urology},
  year = {2025},
  doi = {10.1007/s00345-025-05955-0}
}
Start for free →